|Trade names||Clomid, others|
|Drug class||Selective estrogen receptor modulator; Progonadotropin|
|Metabolism||Liver (with enterohepatic circulation)|
|Elimination half-life||5–6 days|
|Excretion||Mainly urine, some in bile|
|Chemical and physical data|
|Molar mass||405.966 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Clomifene, also known as clomiphene, is a medication used to treat infertility in women who do not ovulate. This includes those who have polycystic ovary syndrome. Use results in a greater chance of twins. It is taken by mouth once a day.
Common side effects include pelvic pain and hot flushes. Other side effects can include changes in vision, vomiting, trouble sleeping, ovarian cancer, and seizures. It is not recommended in people with liver disease or who are pregnant. Clomifene is in the selective estrogen receptor modulator (SERM) family of medication. It works by causing the release of GnRH by the hypothalamus, and subsequently gonadotropin from the anterior pituitary.
Clomifene was approved for medical use in the United States in 1967. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is about 0.79 to 2.00 USD for a course of treatment. In the United States the wholesale cost of a course of treatment is 4.80 USD. Its introduction began the era of assisted reproductive technology.
Clomifene is useful in those who are infertile due to anovulation or oligoovulation. Evidence is lacking for the use of clomifene in those who are infertile without a known reason. In such cases, studies have observed a clinical pregnancy rate 5.6% per cycle with clomifene treatment vs. 1.3%–4.2% per cycle without treatment.
The following procedures may be used to monitor induced cycles:
- Follicular monitoring with vaginal ultrasound, starting 4–6 days after last pill. Serial transvaginal ultrasound can reveal the size and number of developing follicles. It can also provide presumptive evidence of ovulation such as sudden collapse of the preovulatory follicle, and an increase in fluid volume in the rectouterine pouch. After ovulation, it may reveal signs of luteinization such as loss of clearly defined follicular margins and appearance of internal echoes.
- Serum estradiol levels, starting 4–6 days after last pill
- Post-coital test 1–3 days before ovulation to check whether there are at least 5 progressive sperm per HPF
- Adequacy of LH surge by urine LH surge tests 3 to 4 days after last clomifene pill
- Mid-luteal progesterone, with at least 10 ng/ml 7–9 days after ovulation being regarded as adequate.
Repeat dosing: This 5-day treatment course can be repeated every 30 days. The dosage may be increased by 50-mg increments in subsequent cycles until ovulation is achieved. It is not recommended by the manufacturer to use clomifene for more than 6 cycles.
It is no longer recommended to perform an ultrasound examination to exclude any significant residual ovarian enlargement before each new treatment cycle.
Clomifene is sometimes used in the treatment of male hypogonadism as an alternative to testosterone replacement therapy. It has been found to increase testosterone levels by 2- to 2.5-fold in hypogonadal men.
Clomifene has been used in the treatment of gynecomastia. It has been found to be useful in the treatment of some cases of gynecomastia but it is not as effective as tamoxifen or raloxifene for this indication. It has shown variable results for gynecomastia and hence is not recommended for treatment of the condition.
Less common effects (1-10% of people) include visual symptoms (blurred vision, double vision, floaters, eye sensitivity to light, scotomata), headaches, vasomotor flushes (or hot flashes), light sensitivity and pupil constriction, abnormal uterine bleeding and/or abdominal discomfort.
Some studies have suggested that clomifene citrate if used for more than a year may increase the risk of ovarian cancer. This may only be the case in those who have never been and do not become pregnant. Subsequent studies have failed to corroborate those findings.
The incidence of fetal and neonatal abnormalities for patients on clomifene for fertility is similar to that seen in the general population. There is no data to suggest a higher rate of congenital anomalies or spontaneous abortions after using this drug.
Compared to letrozole, another drug used for ovarian stimulation, a study found no significant difference in the rate of overall abnormalities, but found that congenital cardiac anomalies was significantly higher in the clomifene group compared to the letrozole group.
Clomifene is a nonsteroidal SERM that inhibits estrogen receptors in the hypothalamus, inhibiting negative feedback of estrogen on gonadotropin release, leading to up-regulation of the hypothalamic–pituitary–gonadal axis. Zuclomifene, a more active isomer, stays bound for longer periods of time.
In normal physiologic female hormonal cycling, at 7 days past ovulation, high levels of estrogen and progesterone produced from the corpus luteum inhibit GnRH, FSH and LH at the hypothalamus and anterior pituitary. If fertilization does not occur in the post-ovulation period the corpus luteum disintegrates due to a lack of beta-hCG. This would normally be produced by the embryo in the effort of maintaining progesterone and estrogen levels during pregnancy.
Therapeutically, clomifene is given early in the menstrual cycle. It is typically prescribed beginning on day 3 and continuing for 5 days. By that time, FSH level is rising steadily, causing development of a few follicles. Follicles in turn produce the estrogen, which circulates in serum. In the presence of clomifene, the body perceives a low level of estrogen, similar to day 22 in the previous cycle. Since estrogen can no longer effectively exert negative feedback on the hypothalamus, GnRH secretion becomes more rapidly pulsatile, which results in increased pituitary gonadotropin (FSH, LH) release. (More rapid, lower amplitude pulses of GnRH lead to increased LH/FSH secretion, while more irregular, larger amplitude pulses of GnRH leads to a decrease in the ratio of LH/FSH.) Increased FSH level causes growth of more ovarian follicles, and subsequently rupture of follicles resulting in ovulation. Ovulation occurs most often 6–7 days after a course of clomifene.
Clomifene produces N-desmethylclomifene, clomifenoxide (clomifene N-oxide), and 4-hydroxyclomifene as metabolites. The elimination half-life of clomifene is 5 to 6 days. Its metabolites can be detected in feces for up to 6 weeks.
Clomifene is a triphenylethylene derivative. It is a mixture of two geometric isomers, enclomifene ((E)-clomifene) and zuclomifene ((Z)-clomifene). These two isomers have been found to contribute to the mixed estrogenic and antiestrogenic properties of clomifene.
A team at William S. Merrell Chemical Company led by Frank Palopoli synthesized clomifene in 1956; after its biological activity was confirmed a patent was filed and issued in November 1959. Scientists at Merrell had previously synthesized chlorotrianisene and ethamoxytriphetol.
Clinical studies were conducted under an Investigational New Drug Application; it was third drug for which an IND had been filed under the 1962 Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act that had been passed in response to the thalidomide tragedy. It was approved for marketing in 1967 under the brand name Clomid. It was first used to treat cases of oligomenorrhea but was expanded to include treatment of anovulation when women undergoing treatment had higher than expected rates of pregnancy.
The drug is widely considered to have been a revolution in the treatment of female infertility, the beginning of the modern era of assisted reproductive technology, and the beginning of what in the words of Eli Y. Adashi, was "the onset of the US multiple births epidemic".
The company was acquired by Dow Chemical in 1980, and in 1989 Dow Chemical acquired 67 percent interest of Marion Laboratories, which was renamed Marion Merrell Dow. In 1995 Hoechst AG acquired the pharmaceutical business of Marion Merrell Dow. Hoechst in turn became part of Aventis in 1999,:9–11 and subsequently a part of Sanofi. It became the most widely prescribed drug for ovulation induction to reverse anovulation or oligoovulation.
Society and culture
Clomifene is marketed under many brand names worldwide, including Beclom, Bemot, Biogen, Blesifen, Chloramiphene, Clomene, ClomHEXAL, Clomi, Clomid, Clomidac, Clomifen, Clomifencitrat, Clomifene, Clomifène, Clomifene citrate, Clomifeni citras, Clomifeno, Clomifert, Clomihexal, Clomiphen, Clomiphene, Clomiphene Citrate, Cloninn, Clostil, Clostilbegyt, Clovertil, Clovul, Dipthen, Dufine, Duinum, Fensipros, Fertab, Fertec, Fertex, Ferticlo, Fertil, Fertilan, Fertilphen, Fertin, Fertomid, Ferton, Fertotab, Fertyl, Fetrop, Folistim, Genoclom, Genozym, Hete, I-Clom, Ikaclomin, Klofit, Klomen, Klomifen, Lomifen, MER 41, Milophene, Ofertil, Omifin, Ova-mit, Ovamit, Ovinum, Ovipreg, Ovofar, Ovuclon, Ovulet, Pergotime, Pinfetil, Profertil, Prolifen, Provula, Reomen, Serofene, Serophene, Serpafar, Serpafar, Surole, Tocofeno, and Zimaquin.
Clomifene was studied for treatment and prevention of breast cancer, but issues with toxicity led to abandonment of this indication, as did the discovery of tamoxifen. Like the structurally related drug triparanol, clomifene is known to inhibit the enzyme 24-dehydrocholesterol reductase and increase circulating desmosterol levels, making it unfavorable for extended use in breast cancer due to risk of side effects like irreversible cataracts.
- "International brands of clomifene -". Drugs.com. Archived from the original on 20 September 2016. Retrieved 11 September 2016.
- Yilmaz S, Yilmaz Sezer N, Gönenç İM, İlhan SE, Yilmaz E (April 2018). "Safety of clomiphene citrate: a literature review". Cytotechnology. 70 (2): 489–495. doi:10.1007/s10616-017-0169-1. PMID 29159661.
- "Clomiphene Citrate". The American Society of Health-System Pharmacists. Archived from the original on 5 November 2017. Retrieved 8 December 2016.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 385–386. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- Ghumman, Surveen (2015). Principles and Practice of Controlled Ovarian Stimulation in ART. Springer. p. 65. ISBN 9788132216865. Archived from the original on 2016-12-27.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Clomifene". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- "NADAC as of 2016-12-21 | Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Archived from the original on 24 December 2016. Retrieved 26 December 2016.
- Dickey, RP; Holtkamp, DE (1996). "Development, pharmacology and clinical experience with clomiphene citrate" (PDF). Human Reproduction Update. 2 (6): 483–506. doi:10.1093/humupd/2.6.483. PMID 9111183.
- "Use of clomiphene citrate in infertile women: a committee opinion". Fertil. Steril. 100 (2): 341–8. August 2013. doi:10.1016/j.fertnstert.2013.05.033. PMID 23809505.
- Hughes, E; Brown, J; Collins, JJ; Vanderkerchove, P (Jan 20, 2010). "Clomiphene citrate for unexplained subfertility in women". The Cochrane Database of Systematic Reviews (1): CD000057. doi:10.1002/14651858.CD000057.pub2. PMID 20091498.
- Seli, Emre. "Ovulation induction with clomiphene citrate". UpToDate. Archived from the original on 21 December 2016. Retrieved 21 April 2014.
- "Clomifene 50mg Tablets - Summary of Product Characteristics (SPC) - (eMC)". Last updated July 2007: UK Electronic Medicines Compendium. Archived from the original on August 22, 2016. Retrieved September 11, 2016.
- "Clomiphene citrate tablets label" (PDF). Revised October 2012: FDA. Archived (PDF) from the original on September 27, 2016. Retrieved September 11, 2016.
- Trabert, B.; Lamb, E. J.; Scoccia, B.; Moghissi, K. S.; Westhoff, C. L.; Niwa, S.; Brinton, L. A. (2013). "Ovulation-inducing drugs and ovarian cancer risk: Results from an extended follow-up of a large US infertility cohort". Fertility and Sterility. 100 (6): 1660–6. doi:10.1016/j.fertnstert.2013.08.008. PMC 3873340. PMID 24011610.
- Bach, Phil Vu; Najari, Bobby B.; Kashanian, James A. (2016). "Adjunct Management of Male Hypogonadism". Current Sexual Health Reports. doi:10.1007/s11930-016-0089-7. ISSN 1548-3584.
- Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1206–. ISBN 978-0-7817-1750-2.
- Agrawal, Sweety; Ganie, Mohd Ashraf; Nisar, Sobia (2017). "Gynaecomastia": 451–458. doi:10.1007/978-981-10-3695-8_26.
- Nordt CA, DiVasta AD (August 2008). "Gynecomastia in adolescents". Curr. Opin. Pediatr. 20 (4): 375–82. doi:10.1097/MOP.0b013e328306a07c. PMID 18622190.
- Trabert, B; Lamb, EJ; Scoccia, B; Moghissi, KS; Westhoff, CL; Niwa, S; Brinton, LA (Dec 2013). "Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort". Fertility and Sterility. 100 (6): 1660–6. doi:10.1016/j.fertnstert.2013.08.008. PMC 3873340. PMID 24011610.
- Gadducci, A; Guerrieri, ME; Genazzani, AR (Jan 2013). "Fertility drug use and risk of ovarian tumors: a debated clinical challenge". Gynecological Endocrinology. 29 (1): 30–5. doi:10.3109/09513590.2012.705382. PMID 22946709.
- Tulandi T, Martin J, Al-Fadhli R, et al. (June 2006). "Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate". Fertility and Sterility. 85 (6): 1761–5. doi:10.1016/j.fertnstert.2006.03.014. PMID 16650422.
- DrugBank > Clomifene Archived 2011-06-27 at the Wayback Machine. Updated on April 19, 2011
- Duarte FH, Jallad RS, Bronstein MD (November 2016). "Estrogens and selective estrogen receptor modulators in acromegaly". Endocrine. 54 (2): 306–314. doi:10.1007/s12020-016-1118-z. PMID 27704479.
- Analytical Profiles of Drug Substances and Excipients. Academic Press. 20 March 1998. pp. 113–. ISBN 978-0-08-086120-3. Archived from the original on 5 November 2017.
- Allen, R.E., Palopoli, F.P., Schumann, E.L. and Van Campen, M.G. Jr. (1959) U.S. Patent No. 2,914,563 Archived 2016-10-26 at the Wayback Machine, Nov. 24, 1959.
- Holtkamp DE, Greslin JG, Root CA, Lerner LJ (October 1960). "Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene". Proc. Soc. Exp. Biol. Med. 105: 197–201. doi:10.3181/00379727-105-26054. PMID 13715563.
- Hughes E, Collins J, Vandekerckhove P (2000). "Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea". Cochrane Database Syst Rev (2): CD000056. doi:10.1002/14651858.CD000056. PMID 10796477.
- Adashi, Eli Y. (Fall 2014). "Iatrogenic Birth Plurality: The Challenge and Its Possible Solution" (PDF). Harvard Health Policy Review. 14 (1): 9–10. Archived (PDF) from the original on 2016-10-06.
- Lee, Patrick (18 July 1989). "Dow Chemical to Get Control of Marion Labs : $5-Billion-Plus Deal Is an Effort to Diversify". Los Angeles Times. Archived from the original on 29 June 2016.
- Times, Winston Williams, Special To The New York (11 February 1981). "Dow Broadens Product Lines". The New York Times. ISSN 0362-4331. Archived from the original on 6 October 2016.
- "Hoechst AG to Buy Marion Merrell Dow / Acquisition worth over $7 billion". San Francisco Chronicle. Reuters. May 5, 1995. Archived from the original on October 6, 2016.
- Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis Archived 2014-04-21 at the Wayback Machine, Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007
- Timmons, Heather; Bennhold, Katrin (27 April 2004). "France Helped Broker the Aventis-Sanofi Deal". The New York Times. Archived from the original on 5 November 2017.
- Jerome Frank Strauss; Robert L. Barbieri (13 September 2013). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 518–. ISBN 978-1-4557-2758-2. Archived from the original on 5 November 2017.
- The WADA Prohibited List 2016 (listed as clomiphene) Archived 2016-03-06 at the Wayback Machine
- Maximov, PY; Lee, TM; Jordan, VC (May 2013). "The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice". Current clinical pharmacology. 8 (2): 135–55. doi:10.2174/1574884711308020006. PMC 3624793. PMID 23062036.
- Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 13–. ISBN 978-0-12-416676-9. Archived from the original on 5 November 2017.
- Maximov, Philipp Y.; McDaniel, Russell E.; Jordan, V. Craig (2013). "Tamoxifen Goes Forward Alone". Milestones in Drug Therapy: 31–46. doi:10.1007/978-3-0348-0664-0_2. ISSN 2296-6064.